Osteoarthritis, characterised by joint degeneration, stiffness, and pain, affects over 300 million people worldwide. This trend has led to a growing demand for non-surgical solutions like hyaluronic acid intra-articular injections, especially for knee and shoulder treatments. This article explores the uses, benefits, and market insights of HA injections, with a focus on ArtiBest’s unique advantages in treating knee and shoulder arthritis pain.
Table of Contents
Growing Demand for Hyaluronic Acid Injections in Australia’s Osteoarthritis Market
Globally, the market for osteoarthritis treatments is projected to grow at a compound annual growth rate (CAGR) of around 8% over the coming years. In Australia, almost 10% of the population suffers from osteoarthritis, with knee and shoulder osteoarthritis being particularly common. This has driven demand for joint injection therapy as patients seek long-lasting pain relief injections without surgery.
With joint health needs expected to grow at a 13% annual compound growth rate over the next five years, indicating a huge market potential. ArtiBest, MBI’s one-dose intra-articular injection, has successfully obtained TGA certification, promising significant business opportunities for our Australian clients.
Great News! MBI ArtiBest Intra-Articular Injection Receives TGA Approval.
Common Uses of Hyaluronic Acid Injections in Medical Treatment
Hyaluronic acid injections are versatile and can be applied to various joints, offering relief and improved function for patients dealing with joint-related issues. Always consult with a healthcare professional to determine the most appropriate treatment for your specific condition. As the manufacturer of Artibest joint injection products, we are excited to announce that we have successfully obtained sales approval in Australia. This achievement not only enhances our credibility in the market but also allows us to provide healthcare professionals and patients with high-quality, effective treatment options for joint pain.
Hyaluronic acid injections are commonly used to treat joint pain and improve mobility. Here are the key injection areas:
-
Knee Osteoarthritis Treatment: This is the most frequent site for hyaluronic acid injections, particularly effective for alleviating knee pain associated with osteoarthritis and improving overall joint function.
-
Hip Osteoarthritis Treatment: For patients suffering from osteoarthritis of the hip, hyaluronic acid injections can provide essential lubrication, reducing pain and enhancing mobility.
-
Shoulder Osteoarthritis Treatment: These injections are beneficial for shoulder pain and limited range of motion. Research indicates that hyaluronic acid can significantly improve flexibility and reduce discomfort in cases of frozen shoulder (adhesive capsulitis).
-
Ankle Osteoarthritis Treatment: Hyaluronic acid injections can also be administered in the ankle to address degenerative conditions, helping to relieve pain and improve joint function.
Benefits of ArtiBest Hyaluronic Acid Injections
Artibest is designed to deliver superior joint pain relief by leveraging several unique features that set it apart from competing products in the market.
High cross-linking ratio and High Viscosity
Artibest’s High cross-linking ratio and high viscoelasticity are key indicators of its effectiveness in joint injection therapy. The high molecular weight ensures a longer duration within the joint space, resisting enzymatic breakdown more effectively than many lower molecular weight products. Artibest’s viscoelastic properties (G’=517.40 ± 33.48 Pa) provide sustained joint cushioning, offering extended pain relief and improved mobility.
Compared to low-viscosity products, Artibest’s superior viscosity offers greater joint support, allowing for natural movement and comfort. For Australian distributors, this means they can supply a product that is both effective and cost-efficient, as fewer injection sessions are required to maintain patient comfort and joint health.
Low BDDE Residuals for Enhanced Safety
Artibest utilises ECHATM balanced cross-linking technology, which ensures that the cross-linking agent BDDE is uniformly distributed throughout the HA gel. This results in a BDDE residual of less than 0.125(ppm), significantly lower than international safety standards of 0.3ppm. The ultra-low level of BDDE residue minimises the risk of adverse reactions, offering a safe option for elderly patients and those with sensitivities.
For Australian distributors, the high safety standards of Artibest align with healthcare providers’ priorities of delivering quality, low-risk treatments.
Uniform Particle Size and Smooth Injection Experience
Another major advantage of Artibest is its uniform particle distribution, ensuring a consistent and smooth injection experience. The product’s low extrusion force of 9.64N makes it easier to inject, reducing patient discomfort and ensuring a smooth application. For healthcare professionals, ease of administration directly impacts patient experience and reduces the risk of complications during the injection process.
The comfortable injection experience provided by Artibest is a valuable selling point for distributors marketing to healthcare providers who prioritise efficacy and patient comfort.
Clinically Proven Efficacy and Long-Lasting Results
Clinical studies confirm that Artibest provides significant pain reduction and improved joint stability. In trials with knee osteoarthritis patients, Artibest consistently reduced pain and stiffness for up to six months post-treatment. Patients reported less pain when walking on flat surfaces and climbing stairs, with high satisfaction levels throughout the treatment period. Additionally, Artibest maintained joint space stability as shown by X-rays over six months, demonstrating its durability within the joint. For distributors, these long-lasting effects and high satisfaction rates make Artibest an ideal choice, as it meets both practitioner and patient needs in a competitive market.
☛Link to ArtiBest®1-dose Intra-articular Injection
Opportunities and Challenges for Distributors in the Australian Market
Opportunities
Increasing Demand for Non-Surgical Treatments:
With OA cases on the rise, particularly among older adults, HA injections are gaining popularity as a less invasive alternative to surgery.
Single-Dose Preference:
ArtiBest’s single-dose regimen appeals to both patients and clinicians looking for effective treatments with minimal intervention.
Challenges
Regulatory Standards: Australia’s strict regulatory environment may pose challenges in obtaining approvals, though ArtiBest’s existing certifications are a strong advantage.
Price Sensitivity: HA injections can be costly, potentially affecting accessibility for some patients.
